Clinical and Commercialization Developments
PANEL DISCUSSION: Cell, Gene, and Tissue Therapies: Applying Key Lessons from the Evolution and Commercialization of Protein-Based Therapies
After many trials, errors, and milestones, regenerative medicine has become a mainstream part of the biologics industry, supported by at least 670 companies and clinics of all sizes. However, there are many lessons experienced by the protein-based industry that can be applied to further improve commercialization success.
- To introduce and discuss what key lessons can be gleaned from the evolution of traditional bioprocessing to support the optimal future development of regenerative medicines
- To review the rapid changes in bioprocessing materials, operator specialization, and the changing utilization of processing technologies shaping the current therapeutic development pathway
- To propose expectations of what may happen over the next decade of its maturation.
Moderator: BPI Magazine
Anne Montgomery -
Editor In Chief,
BioProcess International Magazine
Philip Vanek, Ph.D. -
General Manager, Cell Therapy Growth Strategy,
Jon Rowley, Ph.D. -
Chief Executive & Technology Officer,
James Miskin -
Chief Technical Officer,